MTOR and fatty liver disease: Our work is only a first attempt to try to explain the possible role of MPEP in liver steatosis, and further studies are required to understand in depth the underling mechanisms in this process, but the hypothesis that MPEP inhibits the mTOR downstream effectors S6K1 and 4E-BP1 may explain in part the increased mTOR activation in the MPEP-treated group; mTORC1 regulates many cellular pathways and trying to blunt its regulatory activity can lead to unexpected feedback loops [55].